Enveric Biosciences (ENVB) Non Operating Investment Income (2022 - 2024)
Enveric Biosciences (ENVB) posted Non Operating Investment Income of $2956.0 for Q4 2024, up 690.02% sequentially from -$501.0 in Q3 2024, and down 99.51% YoY from $608673.0 in Q1 2024.
Enveric Biosciences (ENVB) Non Operating Investment Income (2022 - 2024) Analysis & Trends
Enveric Biosciences has reported Non Operating Investment Income for 3 years, with the latest figure at $2956.0 in Q4 2024.
- Quarterly Non Operating Investment Income fell 99.51% year-over-year to $2956.0 in Q4 2024, while the trailing twelve-month figure through Dec 2024 was $21620.0 (down 89.64% YoY) and the FY2024 annual result came in at $21620.0, down 89.64% from the prior year.
- Non Operating Investment Income improved to $2956.0 in Q4 2024 per ENVB's latest filing, from -$501.0 in the prior quarter.
- Over five years, Non Operating Investment Income peaked at $1.8 million in Q3 2022 and troughed at -$1.1 million in Q2 2023.
- A 3-year average of $370309.8 and a median of $65451.5 in 2023 frame the typical range for Non Operating Investment Income.
- The widest YoY moves for Non Operating Investment Income: up 100.72% in 2024, down 100.09% in 2024.
- Over 3 years, Non Operating Investment Income stood at $1.7 million in 2022, then plunged by 63.4% to $608673.0 in 2023, then tumbled by 99.51% to $2956.0 in 2024.
- According to Business Quant data, Non Operating Investment Income over the past three periods registered $2956.0, -$501.0, and $7767.0 for Q4 2024, Q3 2024, and Q2 2024 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non Operating Investment Income (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | - |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | - |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | - |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | - |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | - |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | - |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | - |
| 10 | Enveric Biosciences | 5.66 Mn | -2.64 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2024 | 2,956.00 |
| Dec 31, 2024 | 2,956.00 |
| Sep 30, 2024 | -501.00 |
| Sep 30, 2024 | -501.00 |
| Jun 30, 2024 | 7,767.00 |
| Jun 30, 2024 | 7,767.00 |
| Mar 31, 2024 | 11,398.00 |
| Mar 31, 2024 | 11,398.00 |
| Dec 31, 2023 | 608,673.00 |
| Dec 31, 2023 | 608,673.00 |
| Sep 30, 2023 | 562,715.00 |
| Sep 30, 2023 | 562,715.00 |
| Jun 30, 2023 | -1.08 Mn |
| Jun 30, 2023 | -1.08 Mn |
| Mar 31, 2023 | 119,505.00 |
| Mar 31, 2023 | 119,505.00 |
| Dec 31, 2022 | 1.66 Mn |
| Dec 31, 2022 | 1.66 Mn |
| Sep 30, 2022 | 1.81 Mn |
| Sep 30, 2022 | 1.81 Mn |